Volume 15, Issue 4 (Winter 2021)
Salmand: Iranian Journal of Ageing 2021, 15(4): 496-505 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Ghasemi A, Mohabati Mobarez A, Mostafavi E. Antibiotic Susceptibility Profile of Clostridium Difficile Bacteria Isolated from Older Residents of a Nursing Home in Iran. Salmand: Iranian Journal of Ageing 2021; 15 (4) :496-505
URL: http://salmandj.uswr.ac.ir/article-1-2052-en.html
URL: http://salmandj.uswr.ac.ir/article-1-2052-en.html
1- Department of Bacteriology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
2- Department of Bacteriology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. ,mmmobarez@modares.ac.ir
3- Department of Epidemiology and Biostatics, Research Centre for Emerging and Reemerging Infectious Diseases, Pasteur Institute of Iran, Tehran, Iran.
2- Department of Bacteriology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. ,
3- Department of Epidemiology and Biostatics, Research Centre for Emerging and Reemerging Infectious Diseases, Pasteur Institute of Iran, Tehran, Iran.
Abstract: (5197 Views)
Objectives: Clostridium difficile (C. diff) is a gram-positive anaerobic bacterium knwon as the most common cause of nosocomial diarrhea in nursing homes. The antibiotic susceptibility profile is the basic way for successful treatment due to antimicrobial resistance. This present study aims to assess the antibiotic susceptibility profile of C. diff isolated from older residents of a nursing home in Tehran, Iran.
Methods & Materials: Forty-two isolates of C. diff were used in this study collected from 289 residents of Kahrizak Nursing Home. Antibiotic susceptibility testing was conducted by using disk-diffusion method, agar dilution method, and Epsilometer test (E-test).
Results: All C. diff strains were susceptible to Metronidazole, Vancomycin, Rifampicin, Linezolid and Tigecycline. By using the disk-diffusion method, the highest rate of resistance was related to Clindamycin (100%), Levofloxacin (96.2%), Imipenem (81%), Azithromycin (61%) and Erythromycin (54.8%). All C. diff strains were susceptible to Metronidazole under E-test. Furthermore, 100% and 59.5% of strains were susceptible to Vancomycin and Erythromycin, respectively under agar dilution test.
Conclusion: C. diff strains are sensitive to Vancomycin and Metronidazole. These two antibiotics can be used to treat C. diff infections in older adults. The disk diffusion method can be used as a screening test to determine antibiotic resistance.
Methods & Materials: Forty-two isolates of C. diff were used in this study collected from 289 residents of Kahrizak Nursing Home. Antibiotic susceptibility testing was conducted by using disk-diffusion method, agar dilution method, and Epsilometer test (E-test).
Results: All C. diff strains were susceptible to Metronidazole, Vancomycin, Rifampicin, Linezolid and Tigecycline. By using the disk-diffusion method, the highest rate of resistance was related to Clindamycin (100%), Levofloxacin (96.2%), Imipenem (81%), Azithromycin (61%) and Erythromycin (54.8%). All C. diff strains were susceptible to Metronidazole under E-test. Furthermore, 100% and 59.5% of strains were susceptible to Vancomycin and Erythromycin, respectively under agar dilution test.
Conclusion: C. diff strains are sensitive to Vancomycin and Metronidazole. These two antibiotics can be used to treat C. diff infections in older adults. The disk diffusion method can be used as a screening test to determine antibiotic resistance.
Type of Study: Research |
Subject:
Clinical
Received: 2020/07/01 | Accepted: 2020/10/31 | Published: 2021/01/01
Received: 2020/07/01 | Accepted: 2020/10/31 | Published: 2021/01/01
References
1. Smits WK, Lyras D, Lacy DB, Wilcox MH, Kuijper EJ. Clostridium difficile infection. Nature reviews Disease primers. 2016;2:16020. [DOI:10.1038/nrdp.2016.20] [PMID] [PMCID]
2. Rodriguez C, Taminiau B, Korsak N, Avesani V, Van Broeck J, Brach P, et al. Longitudinal survey of Clostridium difficile presence and gut microbiota composition in a Belgian nursing home. BMC microbiology. 2016;16(1):229. [DOI:10.1186/s12866-016-0848-7] [PMID] [PMCID]
3. Vincent C, Manges AR. Antimicrobial use, human gut microbiota and Clostridium difficile colonization and infection. Antibiotics. 2015;4(3):230-53. [DOI:10.3390/antibiotics4030230] [PMID] [PMCID]
4. Esfandiari Z, Jalali M, Safaeian L, Weese JS. A review on epidemiology of Clostridium difficile infection. Tehran University Medical Journal TUMS Publications. 2016;74(5):305-13.
5. Hunter JC, Mu Y, Dumyati GK, Farley MM, Winston LG, Johnston HL, et al., editors. Burden of nursing home-onset Clostridium difficile infection in the United States: estimates of incidence and patient outcomes. Open forum infectious diseases; 2016. [DOI:10.1093/ofid/ofv196] [PMID] [PMCID]
6. Crogan NL, Evans BC. Clostridium difficile: An emerging epidemic in nursing homes. Geriatr Nurs. 2007;28(3):161-4. [DOI:10.1016/j.gerinurse.2007.04.005] [PMID]
7. Rodriguez C, Korsak N, Taminiau B, Avesani V, Van Broeck J, Delmée M, et al. Clostridium difficile infection in elderly nursing home residents. Anaerobe. 2014;30:184-7. [DOI:10.1016/j.anaerobe.2014.08.007] [PMID]
8. Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, et al. Guidelines for Diagnosis, Treatment, and Prevention ofClostridium difficileInfections. American Journal of Gastroenterology. 2013;108(4):478-98. [DOI:10.1038/ajg.2013.4] [PMID]
9. Fuchs BB, Tharmalingam N, Mylonakis E. Vulnerability of long-term care facility residents to Clostridium difficile infection due to microbiome disruptions. Future Microbiology. 2018;13(13):1537-47. [DOI:10.2217/fmb-2018-0157] [PMID]
10. Yu H, Baser O, Wang L. Burden of Clostridium difficile-associated disease among patients residing in nursing homes: a population-based cohort study. BMC geriatrics. 2016;16(1):193. [DOI:10.1186/s12877-016-0367-2] [PMID] [PMCID]
11. Kardas P, Devine S, Golembesky A, Roberts C. A systematic review and meta-analysis of misuse of antibiotic therapies in the community. International journal of antimicrobial agents. 2005;26(2):106-13. [DOI:10.1016/j.ijantimicag.2005.04.017] [PMID]
12. Peng Z, Jin D, Kim HB, Stratton CW, Wu B, Tang Y-W, et al. Update on antimicrobial resistance in Clostridium difficile: resistance mechanisms and antimicrobial susceptibility testing. Journal of clinical microbiology. 2017;55(7):1998-2008. [DOI:10.1128/JCM.02250-16] [PMID] [PMCID]
13. Monaghan T, Boswell T, Mahida YR. Recent advances in Clostridium difficile-associated disease. Postgraduate medical journal. 2009;85(1001):152-62. [DOI:10.1136/gut.2007.128157]
14. Hadi A, Mohammad H, Alireza Y, Saman Z. Antibiotic Utilization in Iran 2000-2016: Pattern Analysis and Benchmarking with Organization for Economic Co-operation and Development Countries. Journal of Research in Pharmacy Practice 2019;8(3):162-7. [DOI:10.4103/jrpp.JRPP_19_42] [PMID] [PMCID]
15. Akhi MT, Pirzade T, Naghili B, Gojazade M. Antimicrobial susceptibility of Clostridium difficile isolated from different sources of Imam Reza Hospital, Tabriz. African Journal of Microbiology Research. 2011;5(19):2946-9. [DOI:10.5897/AJMR11.423]
16. Mehdi LY, AL-Mossawei MT. Antibiotic Susceptibility Testing for Clostridium Difficile Iraqi Isolation by using Disk Diffusion Method. Journal of Biology, Agriculture and Healthcare 2015;5(13):156-62.
17. Fraga EG, Nicodemo AC, Sampaio JLM. Antimicrobial susceptibility of Brazilian Clostridium difficile strains determined by agar dilution and disk diffusion. The Brazilian Journal of Infectious Diseases. 2016;20(5):476-81. [DOI:10.1016/j.bjid.2016.07.004] [PMID]
18. Levett P. Antimicrobial susceptibility of Clostridium difficile determined by disc diffusion and breakpoint methods. Journal of Antimicrobial Chemotherapy. 1988;22(2):167-73. [DOI:10.1093/jac/22.2.167] [PMID]
19. Nagy E, Justesen US, Eitel Z, Urbán E. Development of EUCAST disk diffusion method for susceptibility testing of the Bacteroides fragilis group isolates. Anaerobe. 2015;31:65-71. [DOI:10.1016/j.anaerobe.2014.10.008] [PMID]
20. Erikstrup LT, Danielsen T, Hall V, Olsen K, Kristensen B, Kahlmeter G, et al. Antimicrobial susceptibility testing of Clostridium difficile using EUCAST epidemiological cut-off values and disk diffusion correlates. Clinical Microbiology and Infection. 2012;18(8):E266-E72. [DOI:10.1111/j.1469-0691.2012.03907.x] [PMID]
21. Shoaei P, Shojaei H, Jalali M, Khorvash F, Hosseini SM, Ataei B, et al. Clostridium difficile isolated from faecal samples in patients with ulcerative colitis. BMC infectious diseases. 2019;19(1):1-7. [DOI:10.1186/s12879-019-3965-8] [PMID] [PMCID]
22. Weinstein MP, Patel JB, Campeau S, Eliopoulos GM, Galas MF, Humphries RM, et al. Performance standards for antimicrobial susceptibility testing. Clinical and Laboratory Standards Institute. 2018;38.
23. Spigaglia P. Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection. Therapeutic advances in infectious disease. 2016;3(1):23-42. [DOI:10.1177/2049936115622891] [PMID] [PMCID]
24. Poilane I, Bert F, Cruaud P, Nicolas-Chanoine M, Collignon A. Interest of the disk diffusion method for screening Clostridium difficile isolates with decreased susceptibility to antibiotics. Pathologie-biologie. 2007;55(8-9):429. [DOI:10.1016/j.patbio.2007.07.010] [PMID]
25. Huang H, Weintraub A, Fang H, Nord CE. Antimicrobial resistance in Clostridium difficile. International journal of antimicrobial agents. 2009;34(6):516-22. [DOI:10.1016/j.ijantimicag.2009.09.012] [PMID]
26. Goudarzi M, Goudarzi H, Alebouyeh M, Rad MA, Mehr FSS, Zali MR, et al. Antimicrobial susceptibility of Clostridium difficile clinical isolates in Iran. Iranian Red Crescent Medical Journal. 2013;15(8):704. [DOI:10.5812/ircmj.5189] [PMID] [PMCID]
27. Shayganmehr F-S, Alebouyeh M, Azimirad M, Aslani MM, Zali MR. Association of tcdA+/tcdB+ Clostridium difficile genotype with emergence of multidrug-resistant strains conferring metronidazole resistant phenotype. Iranian Biomedical Journal. 2015;19(3):143.
28. Sadeghifard N, Salari MH, Ghassemi MR, Eshraghi S, Harati FA. The incidence of nosocomial toxigenic Clostridium difficile associated diarrhea in Tehran tertiary medical centers. Acta Medica Iranica. 2010:320-5.
29. Shoaei P, Shojaei H, Khorvash F, Hosseini SM, Ataei B, Tavakoli H, et al. Molecular epidemiology of Clostridium difficile infection in Iranian hospitals. Antimicrobial Resistance & Infection Control. 2019;(8)12. [DOI:10.1186/s13756-018-0454-6] [PMID] [PMCID]
30. Norman KN, Scott HM, Harvey RB, Norby B, Hume ME. Comparison of antimicrobial susceptibility among Clostridium difficile isolated from an integrated human and swine population in Texas. Foodborne pathogens and disease. 2014;11(4):257-64. [DOI:10.1089/fpd.2013.1648] [PMID]
31. Simango C, Uladi S. Detection of Clostridium difficile diarrhoea in Harare, Zimbabwe. Transactions of The Royal Society of Tropical Medicine and Hygiene. 2014;108(6):354-7. [DOI:10.1093/trstmh/tru042] [PMID]
32. Oka K, Osaki T, Hanawa T, Kurata S, Okazaki M, Manzoku T, et al. Molecular and microbiological characterization of Clostridium difficile isolates from single, relapse, and reinfection cases. Journal of clinical microbiology. 2012;50(3):915-21. [DOI:10.1128/JCM.05588-11] [PMID] [PMCID]
33. Rodríguez-Pardo D, Almirante B, Bartolomé RM, Pomar V, Mirelis B, Navarro F, et al. Epidemiology of Clostridium difficile infection and risk factors for unfavorable clinical outcomes: results of a hospital-based study in Barcelona, Spain. Journal of clinical microbiology. 2013;51(5):1465-73. [DOI:10.1128/JCM.03352-12] [PMID] [PMCID]
34. Obuch-Woszczatyński P, Lachowicz D, Schneider A, Mól A, Pawłowska J, Ożdżeńska-Milke E, et al. Occurrence of Clostridium difficile PCR-ribotype 027 and it's closely related PCR-ribotype 176 in hospitals in Poland in 2008-2010. Anaerobe. 2014;28:13-7. [DOI:10.1016/j.anaerobe.2014.04.007] [PMID]
35. Krutova M, Matejkova J, Tkadlec J, Nyc O. Antibiotic profiling of Clostridium difficile ribotype 176-A multidrug resistant relative to C. difficile ribotype 027. Anaerobe. 2015;36:88-90. [DOI:10.1016/j.anaerobe.2015.07.009] [PMID]
36. Tian T-t, Zhao J-h, Yang J, Qiang C-x, Li Z-r, Chen J, et al. Molecular characterization of Clostridium difficile isolates from human subjects and the environment. PloS one. 2016;11(3):e0151964.
37. Ngamskulrungroj P, Sanmee S, Pusathit P, Piewngam P, Elliott B, Riley TV, et al. Molecular epidemiology of Clostridium difficile infection in a large teaching hospital in Thailand. PloS one. 2015;10(5):e0127026. [DOI:10.1371/journal.pone.0127026] [PMID] [PMCID]
38. Johanesen PA, Mackin KE, Hutton ML, Awad MM, Larcombe S, Amy JM, et al. Disruption of the gut microbiome: Clostridium difficile infection and the threat of antibiotic resistance. Genes. 2015;6(4):1347 [DOI:10.3390/genes6041347] [PMID] [PMCID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright © The Author(s);
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
